Every New York stock exchange trading day I'm posting a daily dividend stock or fund review. I'll share the three chief qualities of just one equity or fund that could be selected for a dividend stock portfolio I've named the Safari to Sweet Success.

This week my Safari portfolio seeks a company in the healthcare sector. 

That sector includes ten industries all related to testing, diagnosing and treating what ails us. The healthcare industries are: biotechnology; diagnostics & research; drug manufacturers - major; drug manufacturers - specialty & generic; healthcare plans; long-term care facilities; medical care; medical devices, medical distribution; medical supplies.

Today I'm reviewing a drug manufacturer - specialty & generic named Takeda Pharmaceutical Company Limited. Its trading ticker symbol is TKPYY. 

Takeda Pharmaceutical Company Limited is a pharmaceutical company in Japan. Their therapeutic products are in oncology, gastroenterology, cardiovascular, and neurology which are marketed in emerging markets and Europe.  

The company is also involved in clinical diagnostics, chemical products, and other businesses. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan. 

I use three primary keys to gauge dividend equities or funds like Takeda Pharmaceutical (TKPYY): 

(1) Price

(2) Dividends

(3) Returns

TKPYY Price

Takeda Pharmaceutical's price at Friday's market close was $28.28 per share. A year ago its price was $23.31. So it gained$4.97 per share in the past year. If TKPYY does as well this year its share price will increase from $28.28 to $33.25, or about 17.6%.

TKPYY Dividends

Takeda Pharmaceutical's most recent semi-annual dividend was $0.3995 declared September 28th and paid December 11th.  

The annual dividend for 2018 is estimated to be $0.80 payable semi-annually in July,and December.

The yield from that $0.80 annual dividend was almost 2.83% at Friday's $28.28 price.

Any Gains For TKPYY?

Adding the $0.80 dividend to the hypothetical $4.97 estimated year over year price gain shows a potential $5.00 gross gain for the coming year. 

Subtract the cost to trade Takeda Pharmaceutical's (TKPYY) shares: A$1,000.00 investment at Friday's $28.28 price bought 35 shares.

Those 35 shares get hit with broker fees of $5 at purchase and another $5 at sale for a per share cost of about $0.29 per share

Subtract that $0.29 brokerage cost from the estimated $5.00 gross gain leaves a net gain to 2019 of $4.71 X 35 shares = $164.85 or a 16.7% net gain on a $989.80 investment.

Therefore, Pharmaceutical Company Limited (whose ticker symbol is TKPYY), now shows a possible 16.7% gain by my simple year over year calculation with a 2.8% dividend included. Which is below the 3.5% standard for my Safari portfolio.

No analysts cover this stock but the eight-year price chart I saw showed mostly steady price gains.

These forward-looking numbers are conjecture based on past year performance. The actual results remain to be seen. They could turn out to be far lower. More study is required for you to determine if Takeda Pharmaceutical Company Limited (TKPYY ) is worth your time and money.